Novo Nordisk A/S Common Stock · Transaction Sep 10, 2026 · Filed Sep 25, 2026 · $1,001 to $15,000
Novo Nordisk A/S
Follow $NVO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NVO by emailVeridion Score
Why is NVO moving today?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
NVO overview
Related filings and maps
Congress activity in NVO
15 filers · 21 buys · 18 sells (0 labeled S (partial)) · Sep 15, 2015 to Sep 10, 2026 · House 35 / Senate 4
All available history · Latest 5 of 39 lines · Read 2026-10-07T12:56:09.415Z
Novo Nordisk A/S Common Stock · Transaction Aug 31, 2026 · Filed Sep 25, 2026 · $1,001 to $15,000
Novo Nordisk A/S Common Stock · Transaction Aug 26, 2026 · Filed Sep 17, 2026 · $1,001 to $15,000
Novo Nordisk A/S Common Stock · Transaction Mar 30, 2026 · Filed Jul 21, 2026 · $15,001 to $50,000
Novo Nordisk A/S Common Stock · Transaction Oct 31, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
NVO contract awards, year to date.
Public federal awards linked to this ticker.
NVO lobbying filings, year to date.
Registered lobbying filings matched to Novo Nordisk A/S.